Oragenics Inc (OGEN)

$1.39 -0.04 (-2.80%)
Market Cap 1.14M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 141,600
Avg Vol 779,005
Day's Range N/A - N/A
Shares Out 823,000.00
Stochastic %K 47%
Beta 0.95
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
SqueezeThisLemon
SqueezeThisLemon Jul. 28 at 8:38 AM
$OGEN if $VAPE can do it, so can you OGEN ;)
0 · Reply
Seaman23
Seaman23 Jul. 27 at 9:59 PM
$OGEN this stock isnt even worth trolling anymore. ALWAYS TRASH t🗑️🗑️🗑️🚮
0 · Reply
StockFlips
StockFlips Jul. 26 at 12:18 PM
Top swings I am looking at next week🔥 $MEGL $BIYA $NWTG $OGEN $DFSC.TSXV ($DFSC $4.40 close 7/26/25) Be EARLY, don’t be GREEDY 🫵
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 25 at 11:25 PM
$MCVT $OGEN for those that don't believe...
1 · Reply
Rage_monger
Rage_monger Jul. 25 at 9:06 PM
$OGEN You can also submit a complaint online. It’s quick and easy.
0 · Reply
Rage_monger
Rage_monger Jul. 25 at 8:38 PM
$OGEN State of Florida Attorney General
0 · Reply
RocketQueen
RocketQueen Jul. 25 at 7:20 PM
$OGEN been here almost 10 years and the warrants have never been realized. The lenders are shorting the stock with an eye on chapter 11. The only executed warrants will be when the SEC shows up to their location to investigate fraud.
1 · Reply
Rage_monger
Rage_monger Jul. 25 at 6:51 PM
$OGEN Bankruptcy, you mean?
0 · Reply
TCEnterprises
TCEnterprises Jul. 25 at 4:03 PM
$OGEN coming
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 25 at 3:56 PM
$OGEN in watching the video on their website it is very convincing. Unlike most drugs being denied by the FDA. This product is not a "cure", as it's not a condition. They only have to prove that the drug as they say "treat", "intervene", "interrupt " what is going on with the brain. So basically, reduces swelling. Shouldn't be hard
0 · Reply
Latest News on OGEN
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 11 days ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 25 days ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 26 days ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 2 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 2 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 3 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 4 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 4 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 5 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 5 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 5 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 6 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 6 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 7 months ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 10 months ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 10 months ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 10 months ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 11 months ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 11 months ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 1 year ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 1 year ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 1 year ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 1 year ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Jun 5, 2023, 4:18 PM EDT - 2 years ago

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Oragenics to Participate in the World Vaccine Congress Washington

Mar 29, 2023, 11:45 AM EDT - 2 years ago

Oragenics to Participate in the World Vaccine Congress Washington

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Mar 14, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Mar 8, 2023, 9:09 AM EST - 2 years ago

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

SqueezeThisLemon
SqueezeThisLemon Jul. 28 at 8:38 AM
$OGEN if $VAPE can do it, so can you OGEN ;)
0 · Reply
Seaman23
Seaman23 Jul. 27 at 9:59 PM
$OGEN this stock isnt even worth trolling anymore. ALWAYS TRASH t🗑️🗑️🗑️🚮
0 · Reply
StockFlips
StockFlips Jul. 26 at 12:18 PM
Top swings I am looking at next week🔥 $MEGL $BIYA $NWTG $OGEN $DFSC.TSXV ($DFSC $4.40 close 7/26/25) Be EARLY, don’t be GREEDY 🫵
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 25 at 11:25 PM
$MCVT $OGEN for those that don't believe...
1 · Reply
Rage_monger
Rage_monger Jul. 25 at 9:06 PM
$OGEN You can also submit a complaint online. It’s quick and easy.
0 · Reply
Rage_monger
Rage_monger Jul. 25 at 8:38 PM
$OGEN State of Florida Attorney General
0 · Reply
RocketQueen
RocketQueen Jul. 25 at 7:20 PM
$OGEN been here almost 10 years and the warrants have never been realized. The lenders are shorting the stock with an eye on chapter 11. The only executed warrants will be when the SEC shows up to their location to investigate fraud.
1 · Reply
Rage_monger
Rage_monger Jul. 25 at 6:51 PM
$OGEN Bankruptcy, you mean?
0 · Reply
TCEnterprises
TCEnterprises Jul. 25 at 4:03 PM
$OGEN coming
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 25 at 3:56 PM
$OGEN in watching the video on their website it is very convincing. Unlike most drugs being denied by the FDA. This product is not a "cure", as it's not a condition. They only have to prove that the drug as they say "treat", "intervene", "interrupt " what is going on with the brain. So basically, reduces swelling. Shouldn't be hard
0 · Reply
profitingstocks
profitingstocks Jul. 25 at 3:49 PM
$OGEN stating genuine facts about the company is “deceiving people” but bulls posting every day that “tomorrow will be huge” is just fine?
1 · Reply
NMax
NMax Jul. 25 at 3:44 PM
$OGEN Look at that Shorts got their sweetheart deal from Janet and the board. Since the preferred share/warrant (toxic convertible) offering the float has increased by 100,000+ shares. Short interest shockingly dropped off a cliff. Short borrowing fees are easing. All the stuff we knew would happen if Oragenics was facilitating short covering.
0 · Reply
Dh15708
Dh15708 Jul. 25 at 3:06 PM
$OGEN waffly quiet here 😅.
0 · Reply
Billions2020
Billions2020 Jul. 25 at 2:11 PM
$OGEN any doubt they will further dilute just to raise additional cash ??? Any insight appreciated. I do know they did a raise warrants at 2.50, but still not fully confident. Unless they finally get a BO
2 · Reply
SXCross
SXCross Jul. 25 at 1:38 PM
$OGEN I bought another 1,000 shares. The stock is way too cheap. Cash 16 million, market capitalization 1 million.
0 · Reply
Esada
Esada Jul. 25 at 1:34 PM
$OGEN if I lost my ass I definitely wouldn't come to tell the world how bad I suck no one would.
2 · Reply
tequillasunrise
tequillasunrise Jul. 25 at 1:26 PM
$OGEN Robinhood put an alert "OGEN not meeting listing standards" rutt rooo shaggy...
1 · Reply
profitingstocks
profitingstocks Jul. 25 at 11:49 AM
$OGEN Classic shady bio scam tactic, warrants at $2.50 is not a good thing. The lenders are currently shorting the stock imo
0 · Reply
SqueezeThisLemon
SqueezeThisLemon Jul. 24 at 9:00 PM
$OGEN perfect entry. Quiet before the storm
1 · Reply
Msrbutch
Msrbutch Jul. 24 at 8:21 PM
$OGEN
0 · Reply
FAYKAR
FAYKAR Jul. 24 at 8:10 PM
$OGEN 395k volume relative volume is 1,67
0 · Reply
MGAP
MGAP Jul. 24 at 8:04 PM
$OGEN in
0 · Reply